Dr. Eskelund Discusses TP53 Mutated Mantle Cell Lymphoma

Christian Winther Eskelund, MD
Published: Wednesday, Jun 28, 2017



Christian Winther Eskelund, MD, Copenhagen University Hospital, Rigshospitalet, discusses TP53-mutated mantle cell lymphoma (MCL).

TP53 has been associated with poor outcomes in many different cohorts of MCL, says Eskelund.

Eskelund suggests that TP53 status should be measured upfront in patients who are diagnosed with MCL. As clinical trials become available, treating physicians should highly consider entering their patients onto them.
 


Christian Winther Eskelund, MD, Copenhagen University Hospital, Rigshospitalet, discusses TP53-mutated mantle cell lymphoma (MCL).

TP53 has been associated with poor outcomes in many different cohorts of MCL, says Eskelund.

Eskelund suggests that TP53 status should be measured upfront in patients who are diagnosed with MCL. As clinical trials become available, treating physicians should highly consider entering their patients onto them.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Cancer Summaries and Commentaries™: Update from Chicago: Advances in the Treatment of Breast CancerJul 31, 20181.0
Community Practice Connections™: The Next Generation in Renal Cell Carcinoma Treatment: An Oncology Nursing Essentials WorkshopJul 31, 20181.5
Publication Bottom Border
Border Publication
x